The spectrum of skin diseases that occurs in the oncology patient differs somewhat from that seen in other immunosuppressed populations. We review the cutaneous manifestations of invasive mold infections in the leukemia/lymphoma population.

Inpatient hospital consult dermatology (inpatient dermatology), as considered by private practicing dermatologists, remains an often under-recognized, overlooked, and yet extremely important aspect of dermatology as a medical subspecialty.

Diagnosis and management of adverse drug reactions constitutes a significant portion of U.S. health care costs. The clinical presentation of these reactions varies from self-limited, morbilliform drug eruptions to more severe, systemic reactions, such as drug hypersensitivity syndromes, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which are associated with significant mortality.

Severe cutaneous adverse reactions, though rare, represent
a mucocutaneous presentation of adverse drug
responses associated with significant morbidity and mortality.
Here, we review the recent literature highlighting the
roles of selective immune responses, genetic factors, and
drug metabolism in increasing susceptibility of a given
patient to these rare and severe reactions. Further understanding
of these factors and their relative contributions to
a severe drug reaction may hold important implications
for future patient-specific pharmacogenomic and immunologic
profiling in an effort to personalize prescribing patterns
by clinicians. Emerging concepts, such as the role of
viral reactivation and the presence of overlapping clinical
features in severe drug eruptions, are also discussed.

Use of TD in the inpatient setting is emerging as a potentially effective method of triage, assistance, or providing dermatologic consultative services.